Literature DB >> 27512050

Cognitive impairment among patients with multiple sclerosis: associations with employment and quality of life.

J Campbell1, W Rashid2, M Cercignani1, D Langdon3.   

Abstract

OBJECTIVES: To explore the relationship between cognitive impairment and conventional measures of disability in multiple sclerosis (MS), quality of life (QOL) and employment status using the brief international cognitive assessment for multiple sclerosis (BICAMS) in the routine outpatient clinic.
METHODS: 62 patients with MS were assessed on the BICAMS test battery for cognitive impairment. Data were obtained on employment status and a number of questionnaires completed including fatigue severity score, multiple sclerosis neuropsychological questionnaire, hospital anxiety and depression scale, the functional assessment of multiple sclerosis (FAMS) as well as on the EuroQOL five dimension questionnaire (EQ-5D). Other assessments include the patient activation measure and unidimensional self-efficacy scale for multiple sclerosis.
RESULTS: Cognitive assessment revealed 44 subjects (65%) had evidence of cognitive impairment on formal testing. In comparison with patients without evidence of cognitive impairment, cognitively impaired patients exhibited significantly higher rates of unemployment (p=0.009). The symbol digits modalities test was the most significant predictor of unemployment. Cognitive impairment was associated with lower QOL scores on the FAMS (p=0.001) and EQ-5D (p<0.001).
CONCLUSIONS: BICAMS provides a sensitive and easy to administer screening test for cognitive impairment within the outpatient setting. Cognitive impairment is common in our cohort of patients with MS attending outpatients and appears to be associated with increased rates of unemployment and lower measures of QOL. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  NEUROLOGY

Mesh:

Year:  2016        PMID: 27512050     DOI: 10.1136/postgradmedj-2016-134071

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  22 in total

Review 1.  Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.

Authors:  Cindy J Nowinski; Deborah M Miller; David Cella
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

3.  The Italian validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the application of the Cognitive Impairment Index scoring procedure in MS patients.

Authors:  Ornella Argento; Chiara C Incerti; Maria E Quartuccio; Giuseppe Magistrale; Ada Francia; Carlo Caltagirone; Valerio Pisani; Ugo Nocentini
Journal:  Neurol Sci       Date:  2018-04-27       Impact factor: 3.307

4.  Changes in Cognitive Performance With Age in Adults With Multiple Sclerosis.

Authors:  Jessica F Baird; Katie L J Cederberg; E Morghen Sikes; Brenda Jeng; Jeffer E Sasaki; Brian M Sandroff; Robert W Motl
Journal:  Cogn Behav Neurol       Date:  2019-09       Impact factor: 1.600

5.  Validity of the Italian multiple sclerosis neuropsychological screening questionnaire.

Authors:  Simone Migliore; Doriana Landi; Francesca Proietti; Giulia D'Aurizio; Ferdinando Squitieri; Giorgia Mataluni; Carolina Gabri Nicoletti; Giuseppe Curcio; Girolama Alessandra Marfia
Journal:  Neurol Sci       Date:  2021-03-02       Impact factor: 3.307

6.  Motoric cognitive risk syndrome in people with multiple sclerosis: prevalence and correlations with disease-related factors.

Authors:  Sapir Dreyer-Alster; Shay Menascu; Roy Aloni; Uri Givon; Mark Dolev; Anat Achiron; Alon Kalron
Journal:  Ther Adv Neurol Disord       Date:  2022-07-04       Impact factor: 6.430

7.  microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate.

Authors:  María I Dominguez-Mozo; Ignacio Casanova; Laura De Torres; Yolanda Aladro-Benito; Silvia Perez-Perez; Angel Garcia-Martínez; Patricia Gomez; Sara Abellan; Esther De Antonio; Carlos Lopez-De-Silanes; Roberto Alvarez-Lafuente
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

Review 8.  Treatment and management of cognitive dysfunction in patients with multiple sclerosis.

Authors:  John DeLuca; Nancy D Chiaravalloti; Brian M Sandroff
Journal:  Nat Rev Neurol       Date:  2020-05-05       Impact factor: 42.937

9.  ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study.

Authors:  Farshid Mashayekhi; Saeed Sadigh-Eteghad; Amirreza Naseri; Milad Asadi; Negin Abbasi Garravnd; Mahnaz Talebi
Journal:  Neurol Sci       Date:  2021-06-12       Impact factor: 3.307

Review 10.  Recommendations for cognitive screening and management in multiple sclerosis care.

Authors:  Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.